The defendant used the process established by the Patented Medicines (Notice of Compliance) Regulations to keep the plaintiff’s generic version of the defendant’s patented drug out of the market for two years. Because the defendant’s patent was later invalidated, the plaintiff became entitled under s. 8(1) of the Regulations to recover the damages it suffered… Continue reading Apotex Inc. v. Eli Lilly and Co., 2015 ONCA 305






